SUMMARY Corticosteroids may mediate some of their anti-inflammatory effects via induction of a specific 38 kD protein, lipocortin-1. Autoantibodies to lipocortin-1 were measured by enzyme linked immunosorbent assay (ELISA) in 90 healthy subjects and in 63 patients with rheumatoid arthritis (RA), 36 with systemic lupus erythematosus (SLE), 26 with polymyalgia rheumatica, and 13 with chronic airways disease. Sixteen patients with RA receiving prolonged, high steroid doses (prednisolone >7*5 mg/day) had raised IgM antilipocortin-1 levels, while 19 patients with RA untreated with steroids had normal levels. This association was independent of disease activity. In SLE, raised antilipocortin-1 levels were associated with active disease and were independent of steroid treatment. Antilipocortin-1 antibody levels were not raised in patients with polymyalgia rheumatica and chronic airways disease. Thus steroid treatment alone appears insufficient to induce antilipocortin-1 antibodies, unless an underlying autoimmune state is also present. In RA, antilipocortin-1 antibodies may impair anti-inflammatory actions of steroids and render some patients 'steroid resistant'.
Corticosteroids are potent anti-inflammatory drugs frequently used in the treatment of a wide range of rheumatic and other disorders. Their mode of action is multifactorial but in general requires the induction of specific genes within the cell nucleus and subsequent formation of new proteins. One such steroid induced protein is lipocortin-1,1 a 38 kD molecule originally identified as lipomodulin2 or macrocortin.3
Lipocortin-1 inhibits phospholipase A2 activity in in vitro assays and thus suppresses the generation of phospholipid derived inflammatory mediators, including prostaglandins, thromboxanes, and leucotrienes. The mechanism by which lipocortin-1 exerts its antiphospholipase A2 effect is uncertain, as recent data imply an indirect inhibition of enzyme activity where lipocortin competes with enzyme for its phospholipid substrate.5 A family of six distinct lipocortin-like proteins has recently been described, with highly conserved sequences. They have common calcium and phospholipid binding properties with a conserved fourfold repeat structure, suggesting a common functional element, though the exact nature of this is not yet determined. 6 Although corticosteroids are frequently used in the treatment of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and polymyalgia rheumatica, the clinical observation of high corticosteroid requirements for control of inflammatory disease in some patients has long been recognised.7 Furthermore, the 'steroid pseudorheumatism' syndrome in RA may occur with prolonged penods of corticosteroid treatment at doses of prednisolone greater than 7-5 mg/day. (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) 19(9-27) Erosions (n)t 17 26 15 Nodules (n) 4 16 12 Seropositive (n) 1" 26 15 Extra-articular disease (n) 5 13 7 Recent rheumatoid factor level (IU/ml)t 188(60-392) 89 134(29-422) Active joint areast 8 (6) (7) (8) (9) (10) (11) (12) 5 (3) (4) (5) (6) (7) (8) 6 (2) (3) (4) (5) (6) (7) (8) (9) Immunosuppressive drugs (n) 16 (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) ARAt criteria 6 4 6 ANAt titret 640(40-640) 160(4(}640) 400(40-640) Anti-dsDNA (U/ml)t 24(14-38) 15 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) 30 Active disease (n) 6 4 9 Immunosuppressive drugs (n) 0 2 4 *SLE-NIL=patients who had never received corticosteroids; SLE-LOW=patients receiving prednisolone <7-5 mg/day;
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Rheumatoid patients were assessed for seropositivity, radiological erosions, presence of rheumatoid nodules, and other extra-articular manifestations. The number of active joints areas (swollen and tender) and duration of early morning stiffness were assessed as clinical markers of disease activity. All patients with RA were receiving stable non-steroidal anti-inflammatory drug treatment with or without analgesic drugs, and most rheumatoid patients receiving maintenance corticosteroids were also taking disease modifying drugs, including immunosuppressives. Patients with SLE were clinically and serologically assessed for evidence of disease activity within the preceding three months, according to a composite score of various parameters: group A criteria included active synovitis, cutaneous disease, serositis, pulmonary disease, deteriorating renal function (active urine sediment, proteinuria >500 mg/24 h, falling creatinine clearance), active cerebral disease without other identifiable cause, myositis (proximal limb weakness and raised creatine kinase enzymes or abnormal electromyography), vasculitis, or fever without other identifiable cause; group B criteria included arthralgia, myalgia, neutropenia <2-Ox 109/l, lymphopenia <1 Ox 109/l, and hypocomplementaemia. Inactive SLE was defined as none of the above features, whereas active disease was defined as 1 group A criterion or two criteria from group B.
Laboratory investigations included plasma viscosity, C reactive protein, rheumatoid factor assessed by nephelometry (Hyland, normal range 040 IU/ml), antinuclear antibodies by immunofluorescence using HEp2 cells, anti-dsDNA by modified Farr assay (Amersham; normal 0-25 U/ml, anticardiolipin antibody binding levels by ELISA, 15 and immune precipitins to extractable nuclear antigens identified by Ouchterlony immunodiffusion technique or counterimmunoelectrophoresis.
Patients requiring corticosteroids were given the lowest possible maintenance dose to achieve control of the underlying inflammatory disease. The current corticosteroid dose, duration of corticosteroid treatment, and duration of treatment with prednisolone >7-5 mg/day (a semiquantitative assessment of the need for high maintenance corticosteroid treatment) were analysed. Concurrent disease modifying treatment, including immunosuppressive drugs, was also assessed.
RECOMBINANT HUMAN LIPOCORTIN-1
Recombinant human lipocortin-1 was produced in Escherichia coli10 and purified (>99%) by methods described previously. 16 The purified protein was supplied in 25 mM TRIS-HC1 buffer pH 7-7 with 0-1-5 mM EDTA and 0-1 mg/ml human serum albumin (essentially globulin free). Preparations contained less than 50 pg/ml endotoxin. E coli of the same strain, but lacking the lipocortin-1-containing plasmid, were processed in parallel using a method identical with that used for recombinant lipocortin-1. This was used in the ELISA as a 'sham' control coating material. (Table 1) were matched for age, sex distribution, active joint inflammation, and the presence of erosive disease, extra-articular manifestations, and rheumatoid factor. Similarly the patient groups with SLE (Table 2) were matched for age, sex distribution and number of American Rheumatism Association criteria. The SLE-NIL and the SLE-HIGH groups had more active disease, however, than the SLE-LOW group. The median age of the group with chronic airways disease (10 men, three women) was 65 years, and the median duration of disease was 24 years (interquartile range 11-35 years). None had an autoimmune disease. The group with polymyalgia rheumatica (five men, 21 women) were older (median age 70 years) and had shorter duration of disease (median three years, interquartile range 2-6 years).
Despite prolonged corticosteroid treatment in the groups with chronic airways disease and polymyalgia rheumatica (Table 4) and high corticosteroid requirements, particularly in the group with chronic airways disease (median prednisolone dose 15 mg/day), levels of antilipocortin-1 antibodies did not differ from control values (Figs 1, 2) . Antilipocortin-1 binding levels in RA-NIL patients were also similar to those in healthy controls. Patients with RA taking corticosteroids, however, had significantly increased antilipocortin-1 levels, particularly IgM, notably in the RA-HIGH group. Levels of IgM antilipocortin-1 binding were associated with daily prednisolone dose and with duration of treatment with prednisolone >7-5 mg/day goo] (p<005). Total duration of corticosteroid use was longer in the RA-HIGH group than for the RA-LOW patients (Table 4 ), but this difference was not statistically significant. There were no correlations between antilipocortin-1 IgM or IgG levels and age, rheumatoid disease activity assessed clinically or biochemically (plasma viscosity, C reactive protein), or other autoantibodies, including serum rheumatoid factor, antinuclear antibodies, and antidsDNA binding. In addition, the presence of IgM rheumatoid factor in combination with raised levels of IgG antilipocortin-1 was not associated with the presence of high IgM antilipocortin-1 activity. Thus measurement of the latter was not susceptible to interference by rheumatoid factor binding to IgG antilipocortin-1 in the ELISA assay.
In SLE significantly increased binding of both IgM and IgG antilipocortin-1 antibodies was present not only in the SLE-HIGH group but also in the patients with SLE who had never received corticosteroids (Table 4 ; Figs 1, 2) . Furthermore, raised levels of IgM antilipocortin-1 were significantly associated with inflammatory disease activity (p<0-01) in the overall SLE population. Eighteen patients with SLE with inactive disease had a median IgM antilipocortin-1 level of 27 (interquartile range 16-59) ELISA units/ml, whereas 18 patients with active SLE had a median level of 97 (61-158) (p<0-01, Mann-Whitney U test). No correlations were detected between antilipocortin-1 antibodies and corticosteroid dosage, disease duration, or serological parameters (antinuclear antibodies, anti-dsDNA, anticardiolipin levels, or immune precipitins to extractable nuclear antigens). Concurrent immunosuppressive or second line agents, including 26 Despite prolonged, high dose maintenance corticosteroid treatment in chronic airways disease (and in polymyalgia rheumatica) these patients did not have raised levels of antilipocortin-1 antibodies (Table 4 ). This suggests that other mechanisms are responsible for corticosteroid resistant asthma. 14 Recent evidence suggests that defective monocyte responsiveness to corticosteroids may be important in reducing their therapeutic effect in these asthmatic patients.27 28 These observations, together with normal antilipocortin-1 autoantibody levels in steroid treated patients with polymyalgia rheumatica, indicate that the nature of the underlying autoimmune disorder is important in the generation of such autoantibodies.
We suggest that antilipocortin-1 antibodies are clinically significant in patients with RA by impairing the lipocortin-1 mediated inhibition of phospholipase A2 activity. This would result in a functional corticosteroid insufficiency with an increased corticosteroid requirement and thus relative 'steroid resistance'. Evidence supporting a functional role for these antibodies includes work by Hirata et al,9 who showed that antilipocortin-1 antibodies potentiated phospholipase A2 activity and enhanced the stimulatory activity of bradykinin on the release of arachidonic acid in vitro, whereas addition of purified lipocortin-1 overcame these effects. This work, together with observations of enhanced phospholipase A2 activity17 and increased prostanoid release in RA peripheral blood monocytes,'8 suggests that antilipocortin-1 autoantibodies may have important functions in RA inflammatory processes and immune phenomena. Longitudinal studies are in progress to examine autoantibody induction at the start of corticosteroid treatment in patients with RA, as well as the relation between IgM antilipocortin-1 antibody levels and disease activity in SLE. This information may lead to better use of corticosteroids in the treatment of these diseases.
